MC
LLY icon

Moors & Cabot’s Eli Lilly LLY Stock Holding History

Moors & Cabot’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2
Closed -$3K – 945
2021
Q4 		$3K Buy
+2
New +$507 ﹤0.01% 884

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Moors & Cabot's LLY Position: Q1 2026 in Review

Moors & Cabot reduced its Eli Lilly (LLY) stake by 0.23% in Q1 2026, selling an estimated $53.7K and leaving 23,250 shares worth $21.4M. The position accounts for 0.92% of the portfolio, ranked #15.

Moors & Cabot first reported a position in LLY in Q1 2014 and has held it in 49 quarters since. The position peaked at $25M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Moors & Cabot held 23,250 shares of Eli Lilly worth $21.4M as of Q1 2026.
  • Moors & Cabot sold 53 Eli Lilly shares in Q1 2026, an estimated $53.7K.
  • Eli Lilly made up 0.92% of Moors & Cabot's portfolio in Q1 2026, its #15 holding.
  • Moors & Cabot first reported a position in Eli Lilly in Q1 2014 and has held it in 49 quarters since.
  • Moors & Cabot's Eli Lilly position peaked at $25M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.